GRCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Grace Therapeutics, Inc (GRCE) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has experienced a significant price drop due to the FDA's rejection of its key drug application, and the company's financials show declining performance. Additionally, technical indicators point to a bearish trend, and there are no strong positive catalysts to offset the negative sentiment.
The stock is in a bearish trend with a MACD histogram of -0.103, indicating negative momentum. The RSI is at 15.943, signaling an oversold condition, but this does not guarantee a reversal. Moving averages are converging, and the stock is trading below key support levels (S1: 2.403, S2: 1.631), suggesting further downside risk.
The FDA does not require additional clinical data for the GTx-104 drug application, which could reduce the time and cost for resubmission.
The FDA rejected the New Drug Application for GTx-104 due to issues in chemistry, manufacturing, and controls, leading to a 45% drop in stock price. This rejection significantly impacts the company's growth prospects and investor confidence.
In Q3 2026, the company reported a net income loss of -$2,315,000, down 44.28% YoY, and an EPS of -0.14, down 61.11% YoY. Revenue and gross margin remain at 0, indicating no meaningful revenue generation.
No recent analyst ratings or price target changes are available for GRCE.
